1. [1] Chun R, Garrett LD, Vail DM : Withrow and MacEwen's Small Animal Clinical Oncology 4th ed,163-188, WB Saunders, Philadelphia (2007)
2. [3] Hagiwara A, Takahashi T, Sawai K, Iwamoto A, Shimotsuma M, Yoneyama C, Seiki K, Itoh M, Sasabe T,Lee M : Lymph nodal vital staining with newer carbon particle suspensions compared with India ink :Experimental and clinical observaions, Lymphology 25, 84-89 (1992)
3. [7] Takahashi T, Mizuno M, Fujita Y, Ueda S, Nishioka B, Majima S : Increased concentration of anticancer agents in regional lymphnodes by fat emulsions, with special reference to chemotherapy of metastasis,Gann, 64, 345-350 (1973)
4. [8] Hagiwara A, Takahishi T, Sawai K, Sakakura C, Hoshima M, Ohyama T, Ohgaki M, Imanishi T,Yamamoto A, Muranishi S : Methotrexate bound to carbon particles used for treating cancers with lymph node metastases in animal experiments and clinical pilot study, Cancer, 78, 2199-2209 (1996)
5. [9] Ballard BE : Biopharmaceutical considerations in subcutaneous and intramuscular drug administration, J Pharm Sci 57, 357-378 (1968)